- Amphastar Pharmaceuticals has several key growth drivers: a strong pipeline of products currently awaiting approval, exciting products with growing sales, and growing marketing and distribution channels.
- With approvals for its developed products pending, AMPH could anticipate doubling its revenues if it can obtain those approvals on time.
- Based on base-case growth of 8 to 11% modeled using discounted cash flows, AMPH has an upside of 42.3%.
- Investors looking to add undervalued pharmaceutical companies to their portfolios should consider an investment in AMPH.
For further details see:
Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio